ReviewClinical and experimental medicine2025
Regulatory roles of non-coding and exosomal RNAs in colorectal cancer: spotlight on angiogenesis.
Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- H19 and the PD-1/PD-L1 Axis in hepatocellular carcinoma and colorectal cancer: emerging evidence, mechanistic links, and therapeutic perspectives.Clinical and experimental medicine · 2026Review
- MicroRNA-VEGF axis in gastric cancer: a novel therapeutic frontier.Discover oncology · 2026Review
- Exerkine-loaded exosomes in muscle aging: a nexus of exercise, regeneration, and crosstalk.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a primary contributor to cancer-related mortality, largely due to its high metastatic potential. Although traditional treatments like surgery and chemotherapy have advanced, therapeutic resistance and relapse remain major challenges. Recent research has revealed that non-coding RNAs (ncRNAs) play pivotal roles in CRC progression, particularly by driving angiogenesis. Several classes of ncRNAs, including lncRNAs, miRNAs, and circRNAs, are key regulators of angiogenesis in CRC. For example, miRNAs such as miR-148a and miR-181a influence the VEGF and HIF-1α signaling pathways, which are critical for endothelial cell proliferation and migration. Certain lncRNAs, such as HNF1A-AS1 and UCA1, interact with miRNAs to modulate these pathways. CircRNAs (e.g., circ_0001821 and circ-ERBIN) often function as "miRNA sponges," sequestering angiogenesis-inhibiting miRNAs to promote tumor vascularization. Furthermore, exosomes act as intercellular communication vesicles that transport ncRNAs (miRNAs, circRNAs) within the tumor microenvironment (TME). This process enables cancer cells to remodel their environment and facilitate metastatic dissemination. Specifically, exosomal ncRNAs, such as circ_0000467 and circ_0081069, can regulate angiogenesis-related pathways. This review integrates current findings on the complex interactions between miRNAs, lncRNAs, circRNAs, and exosomal ncRNAs in CRC angiogenesis. Understanding these molecular regulators highlights their potential as novel diagnostic biomarkers and therapeutic targets, which may lead to new targeted treatments that improve CRC patient outcomes by controlling angiogenesis and metastatic spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.